CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Indication||In combination with rituximab for previously untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL); In combination with obinutuzumab for previously untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL)|
|Review Status||Not Filed|
|Manufacturer||Janssen Canada Inc.|
|Clarification||CADTH is unable to recommend reimbursement of the relevant product because a submission to CADTH was not filed by the manufacturer.|
|Last Updated||July 17, 2019|